# Murray Stewart

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/murray-stewart/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,746 |
| Field | Diabetes Treatment and Management |
| h-index | 36 |
| i10-index | 59 |
| Last Known Institution | Cleveland Clinic |
| OpenAlex ID | https://openalex.org/A5113581999 |
| Works | 89 |

## Researcher papers

- [Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and/)
- [Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials](https://scholariq.org/papers/efficacy-and-safety-of-setmelanotide-an-mc4r-agonist-in-individuals-with-severe/)
- [Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study](https://scholariq.org/papers/once-weekly-albiglutide-versus-once-daily-liraglutide-in-patients-with-type-2/)
- [Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes](https://scholariq.org/papers/potential-of-albiglutide-a-long-acting-glp-1-receptor-agonist-in-type-2-diabetes/)
- [HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin](https://scholariq.org/papers/harmony-3-104-week-randomized-double-blind-placebo-and-active-controlled-trial/)
- [Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro](https://scholariq.org/papers/advancing-basal-insulin-replacement-in-type-2-diabetes-inadequately-controlled/)
- [Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes](https://scholariq.org/papers/pharmacodynamics-pharmacokinetics-safety-and-tolerability-of-albiglutide-a-long/)
- [Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects](https://scholariq.org/papers/safety-tolerability-pharmacodynamics-and-pharmacokinetics-of-albiglutide-a-long/)
- [Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines](https://scholariq.org/papers/speech-and-swallow-rehabilitation-in-head-and-neck-cancer-united-kingdom/)
- [HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea](https://scholariq.org/papers/harmony-4-randomised-clinical-trial-comparing-once-weekly-albiglutide-and/)
- [Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study](https://scholariq.org/papers/efficacy-and-safety-of-the-once-weekly-glp-1-receptor-agonist-albiglutide-versus/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Peroxisome Proliferator-Activated Receptors](https://scholariq.org/topics/peroxisome-proliferator-activated-receptors/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

## Researcher university

- [Cleveland Clinic](https://scholariq.org/institutions/cleveland-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.